Impaired humoral immunity to BQ.1.1 in convalescent and vaccinated patients
-
Published:2023-05-19
Issue:1
Volume:14
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Dewald Felix, Pirkl MartinORCID, Paluschinski MarthaORCID, Kühn Joachim, Elsner CarinaORCID, Schulte BiancaORCID, Knüfer Jacqueline, Ahmadov Elvin, Schlotz Maike, Oral Göksu, Bernhard Michael, Michael Mark, Luxenburger Maura, Andrée Marcel, Hennies Marc Tim, Hafezi Wali, Müller Marlin Maybrit, Kümpers Philipp, Risse JoachimORCID, Kill Clemens, Manegold Randi Katrin, von Frantzki Ute, Richter Enrico, Emmert Dorian, Monzon-Posadas Werner O., Gräff Ingo, Kogej Monika, Büning Antonia, Baum Maximilian, Teipel FinnORCID, Mochtarzadeh Babak, Wolff Martin, Gruell HenningORCID, Di Cristanziano VeronicaORCID, Burst Volker, Streeck Hendrik, Dittmer Ulf, Ludwig StephanORCID, Timm Jörg, Klein FlorianORCID
Abstract
AbstractDetermining SARS-CoV-2 immunity is critical to assess COVID-19 risk and the need for prevention and mitigation strategies. We measured SARS-CoV-2 Spike/Nucleocapsid seroprevalence and serum neutralizing activity against Wu01, BA.4/5 and BQ.1.1 in a convenience sample of 1,411 patients receiving medical treatment in the emergency departments of five university hospitals in North Rhine-Westphalia, Germany, in August/September 2022. 62% reported underlying medical conditions and 67.7% were vaccinated according to German COVID-19 vaccination recommendations (13.9% fully vaccinated, 54.3% one booster, 23.4% two boosters). We detected Spike-IgG in 95.6%, Nucleocapsid-IgG in 24.0%, and neutralization against Wu01, BA.4/5 and BQ.1.1 in 94.4%, 85.0%, and 73.8% of participants, respectively. Neutralization against BA.4/5 and BQ.1.1 was 5.6- and 23.4-fold lower compared to Wu01. Accuracy of S-IgG detection for determination of neutralizing activity against BQ.1.1 was reduced substantially. We explored previous vaccinations and infections as correlates of BQ.1.1 neutralization using multivariable and Bayesian network analyses. Given a rather moderate adherence to COVID-19 vaccination recommendations, this analysis highlights the need to improve vaccine-uptake to reduce the COVID-19 risk of immune evasive variants. The study was registered as clinical trial (DRKS00029414).
Funder
Ministry for work, health, and social affairs of the state of North Rhine-Westphalia
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry,Multidisciplinary
Reference43 articles.
1. Lopez Bernal, J. et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) variant. N. Engl. J. Med. 385, 585–594 (2021). 2. Tseng, H. F. et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat. Med. 28, 1063–1071 (2022). 3. Nyberg, T. et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet 399, 1303–1312 (2022). 4. Tran, T. N. A. et al. SARS-CoV-2 attack rate and population immunity in Southern New England, March 2020 to May 2021. JAMA Netw. Open 5, e2214171–e2214171 (2022). 5. Aziz, N. A. et al. Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies from a population-based study in Bonn, Germany. Nat. Commun. 12, 1–10 (2021).
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|